Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo, Inc. (OTCQB:BLGO) has announced a municipal wastewater treatment pilot for its innovative water treatment technologies, AOS and AEC, to be conducted near Montréal, Québec. This pilot aims to validate the effectiveness and cost-efficiency of these technologies in treating challenging contaminants in real wastewater environments. Funded partly by a $225,000 CAD grant from NSERC, the project is expected to generate initial results by Q1 2021. BioLargo’s technologies previously demonstrated successful wastewater treatment capabilities at a poultry facility in Alberta.
BioLargo, Inc. (OTCQB:BLGO) released its Q2 2020 highlights, coinciding with its 10-Q filing. The company launched Clyraguard, an FDA-registered disinfectant, achieving strong sales growth. It secured a $1 million inventory line and established distribution partnerships. Upcoming projects include a $500,000 revenue-generating AOS water treatment contract and field pilots for PFAS treatment technology. Despite a 2% revenue decrease in Q2, overall revenue rose 8% for the first half of 2020. BioLargo has converted $3.5 million of debt to equity, strengthening its balance sheet.